

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

**TERMINATION OF THE 2023 H SHARE AWARD AND
TRUST SCHEME AND THE REPURCHASE AND
CANCELLATION OF H SHARES**

References are made to (i) the announcement of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated April 24, 2023 (the “**Announcement**”); (ii) the circular of the Company dated April 27, 2023 (the “**Circular**”); and (iii) the poll results announcement of the Company dated May 31, 2023, in relation to, among other things, (a) the adoption of the 2023 H Share Award and Trust Scheme; and (b) the acquisition by the Scheme Trustee of H Shares through on-market transactions. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement and the Circular.

As at the date of this announcement, the Scheme Trustee has acquired 15,467,500 H Shares of the Company through on-market transactions as the source of the Award Shares (the “**Acquired Award Shares**”) with internal funds of the Company, but such Acquired Award Shares have not yet been granted to any Selected Participant.

As the performance growth of the Company is not as anticipated, the management of the Company has proposed to the Board to terminate the 2023 H Share Award and Trust Scheme and repurchase and cancel 15,467,500 H Shares. In consideration of the Repurchase Mandate granted to the Directors to repurchase A Shares and/or H Shares which was considered and approved by the Shareholders at the 2022 AGM, the A Share Class Meeting and the H Share Class Meeting, the “Proposal on the Termination of the 2023 H Share Award and Trust Scheme of the Company and the Repurchase and Cancellation of H Shares” was unanimously approved by the Board at the fourth meeting of the third session of the Board held on October 30, 2023 (particulars of which are set out in the overseas regulatory announcement of the Company in connection with the resolutions passed at the meeting (No. Lin2023-065)), pursuant to which the implementation of the 2023 H Share Award and Trust Scheme shall be terminated and 15,467,500 H Shares shall be repurchased and cancelled. The number of H Shares to be cancelled represents approximately 0.52% of

the total issued share capital of the Company as at the date of this announcement, and the registered share capital of the Company will be reduced by RMB15,467,500 accordingly following the completion of the cancellation.

The Company will follow and comply with relevant approval and filing procedures (if applicable) in accordance with the requirements of applicable laws and regulations of both mainland China and Hong Kong (including but not limited to the Listing Rules and the Rules Governing the Listing of Stocks on Shanghai Stock Exchange), execute documents and take actions or steps deemed appropriate or necessary to facilitate the transfer, repurchase and other relevant administrative matters in relation to the Acquired Award Shares, the repurchase and cancellation of H Shares and the reduction of registered share capital of the Company.

The abovementioned termination of the 2023 H Share Award and Trust Scheme and the repurchase and cancellation of H Shares will not affect the public float of the Company as required under the Listing Rules, nor will it cause material adverse impact on the operational performance of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, October 30, 2023

As at the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.

* *For identification purposes only*